Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Point of Care (PoC) Molecular Diagnostics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of North America Point of Care (PoC) Molecular Diagnostics Market 26
Figure 8. World Number of Deaths by Cause in 2017 29
Figure 9. World Number of Deaths from Cancers in 2017 30
Figure 10. Primary Restraints and Impact Factors of North America Point of Care (PoC) Molecular Diagnostics Market 31
Figure 11. Investment Opportunity Analysis 35
Figure 12. Porter’s Fiver Forces Analysis of North America Point of Care (PoC) Molecular Diagnostics Market 38
Figure 13. Breakdown of North America Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, % of Revenue 43
Figure 14. North America Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%) 44
Figure 15. North America Point of Care (PoC) Molecular Diagnostics Market: Kits & Assays, 2019-2030, $ mn 45
Figure 16. North America Point of Care (PoC) Molecular Diagnostics Market: Analyzers & Instruments, 2019-2030, $ mn 46
Figure 17. North America Point of Care (PoC) Molecular Diagnostics Market: Software & Services, 2019-2030, $ mn 47
Figure 18. Breakdown of North America Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, % of Sales Revenue 48
Figure 19. North America Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 49
Figure 20. North America Point of Care (PoC) Molecular Diagnostics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 50
Figure 21. North America Point of Care (PoC) Molecular Diagnostics Market: Real-Time PCR (rt-PCR), 2019-2030, $ mn 51
Figure 22. North America Point of Care (PoC) Molecular Diagnostics Market: Digital PCR (d-PCR), 2019-2030, $ mn 52
Figure 23. North America Point of Care (PoC) Molecular Diagnostics Market: Isothermal Nucleic Acid Amplification Technology (INAAT), 2019-2030, $ mn 53
Figure 24. North America Point of Care (PoC) Molecular Diagnostics Market: Genetic Sequencing-based Technology, 2019-2030, $ mn 54
Figure 25. North America Point of Care (PoC) Molecular Diagnostics Market: Microarray-based Technology, 2019-2030, $ mn 55
Figure 26. North America Point of Care (PoC) Molecular Diagnostics Market: Other Technologies, 2019-2030, $ mn 56
Figure 27. Breakdown of North America Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, % of Sales Revenue 57
Figure 28. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 58
Figure 29. North America Point of Care (PoC) Molecular Diagnostics Market: Infectious Disease, 2019-2030, $ mn 59
Figure 30. North America Point of Care (PoC) Molecular Diagnostics Market: Respiratory Infections, 2019-2030, $ mn 61
Figure 31. North America Point of Care (PoC) Molecular Diagnostics Market: Hospital Acquired Infections, 2019-2030, $ mn 62
Figure 32. North America Point of Care (PoC) Molecular Diagnostics Market: Sexually Transmitted Infections, 2019-2030, $ mn 63
Figure 33. North America Point of Care (PoC) Molecular Diagnostics Market: Gastrointestinal Infections, 2019-2030, $ mn 64
Figure 34. North America Point of Care (PoC) Molecular Diagnostics Market: Oncology, 2019-2030, $ mn 65
Figure 35. North America Point of Care (PoC) Molecular Diagnostics Market: Hepatitis, 2019-2030, $ mn 66
Figure 36. North America Point of Care (PoC) Molecular Diagnostics Market: Prenatal/Neonatal Testing, 2019-2030, $ mn 67
Figure 37. North America Point of Care (PoC) Molecular Diagnostics Market: Other Applications, 2019-2030, $ mn 68
Figure 38. Breakdown of North America Point of Care (PoC) Molecular Diagnostics Market by End User, 2019-2030, % of Revenue 69
Figure 39. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 70
Figure 40. North America Point of Care (PoC) Molecular Diagnostics Market: Hospitals, 2019-2030, $ mn 71
Figure 41. North America Point of Care (PoC) Molecular Diagnostics Market: Clinics & Diagnostic Centers, 2019-2030, $ mn 72
Figure 42. North America Point of Care (PoC) Molecular Diagnostics Market: Research and Academic Institutes, 2019-2030, $ mn 73
Figure 43. North America Point of Care (PoC) Molecular Diagnostics Market: Other End Users, 2019-2030, $ mn 74
Figure 44. Breakdown of North America Point of Care (PoC) Molecular Diagnostics Market by Country, 2019 and 2030, % of Revenue 77
Figure 45. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 78
Figure 46. U.S. Point of Care (PoC) Molecular Diagnostics Market, 2019-2030, $ mn 80
Figure 47. Canada Point of Care (PoC) Molecular Diagnostics Market, 2019-2030, $ mn 83
Figure 48. Point of Care (PoC) Molecular Diagnostics Market in Mexico, 2015-2030, $ mn 85
Figure 49. Growth Stage of North America Point of Care (PoC) Molecular Diagnostics Industry over the Forecast Period 87
North America PoC molecular diagnostics market is expected to grow by 12.7% annually in the forecast period and reach $2,320.5 million by 2030 driven by increase in adoption of personalized medicine and surge in usage of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic. Highlighted with 27 tables and 49 figures, this 118-page report “North America Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Country. Based on Product, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Kits & Assays • Analyzers & Instruments • Software & Services Based on Technology, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Polymerase Chain Reaction (PCR) • Real-Time PCR (rt-PCR) • Digital PCR (d-PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) Genetic Sequencing-based Technology Microarray-based Technology Other Technologies Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Infectious Disease • Respiratory Infections • Hospital Acquired Infections • Sexually Transmitted Infections Gastrointestinal Infections Oncology Hepatitis Prenatal/Neonatal Testing Other Applications Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals • Clinics & Diagnostic Centers • Research and Academic Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico Detailed analysis and 2019-2030 annual revenue are available for each key national market. The breakdown of key national markets by Product, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America PoC molecular diagnostics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abacus Diagnostica Oy Abbott Laboratories Alere Inc. Biocartis Group NV Biomerieux SA Bio-Rad Laboratories Inc Danaher Corporation DiaSorin S.p.A DxNA LLC. F. Hoffmann-La Roche Ltd. Hologic, Inc. Luminex Corporation Meridian Bioscience Inc. Mesa Biotech Inc. QIAGEN N.V. QuantuMDx Group Ltd. Quidel Corporation Spartan Biosciences Inc. Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More